Packed Red Blood Cell Transfusion During Cardiac Arrest (NCT06462027) | Clinical Trial Compass
SuspendedPhase 1
Packed Red Blood Cell Transfusion During Cardiac Arrest
Stopped: Temporary hold.
United States30 participantsStarted 2026-06-01
Plain-language summary
The purpose of this pilot interventional study is to collect preliminary data on administering packed red blood cell (PRBC) during cardiac arrest (CA). The primary objective is to assess the feasibility of PRBC transfusion during cardiac CA to help optimize the methods required to augment cerebral and other vital organ oxygen delivery during cardiopulmonary resuscitation (CPR). The secondary objectives are to assess the effect of PRBC transfusion during prolonged cardiac arrests on cerebral oxygenation, end tidal carbon dioxide (ETCO2), return of spontaneous circulation (ROSC), survival to discharge, biomarkers of neural injury and inflammation, and neurological outcomes at hospital discharge, 30 days post-CA, and 90 days post-CA.
Who can participate
Age range
18 Years – 85 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Adult patients, age ≥18 and \<85 years
* Experience prolonged, non-trauma-related in-hospital cardiac arrest, defined by cessation of heartbeat and respiration requiring CPR for at least 10 minutes
Exclusion Criteria:
* Age \<18 years old
* Age \> 85 years old
* Patients with DNR/DNI orders (Do Not Resuscitate/Do Not Intubate)
* Patients admitted to the hospital with a cardiac arrest arising from trauma
* Patients who achieve return of spontaneous circulation within 10 minutes of CPR
* Inability to start study product administration within 20 minutes of cardiac arrest onset
* Prisoners
* Women who are known to be pregnant
* Patients with a history of RBC antibodies or positive antibody screen prior to enrollment in the study, unless previously cross-matched units are available for transfusion.
* Patients with ultrasound evidence of right ventricular dilatation at time of CA
* Patients with known prior objection to receipt of blood products.
* Patients for whom administration of additional fluid volume is contraindicated (as determined by physician responsible for care)
* Physician objection based on concern that intervention would interfere with patient care plan
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Time (in mins) to administration of Packed Red Blood Cells (PRBC)
Timeframe: During Cardiopulmonary Resuscitation (CPR) (up to 20 minutes)
2
Frequency of antibody-mediated transfusion reactions
Timeframe: 6-72 hours after Return of Spontaneous Circulation (ROSC)
3
Frequency of non-immune reactions
Timeframe: 6-72 hours after ROSC
4
Change in frequency of right ventricular (RV) dilatation
Timeframe: Baseline, up to 20 minutes post administration of PRBC
5
All-cause mortality
Timeframe: Up to 30 days after the last day of study participation
6
Proportion of patients with unfavorable neurological outcomes